Who Optimizes SG&A Costs Better? Cytokinetics, Incorporated or ACADIA Pharmaceuticals Inc.

Biotech Giants: Who Manages SG&A Costs Better?

__timestampACADIA Pharmaceuticals Inc.Cytokinetics, Incorporated
Wednesday, January 1, 20143274800017268000
Thursday, January 1, 20159080400019667000
Friday, January 1, 201618645600027823000
Sunday, January 1, 201725506200036468000
Monday, January 1, 201826575800031282000
Tuesday, January 1, 201932563800039610000
Wednesday, January 1, 202038866100052820000
Friday, January 1, 202139602800096803000
Saturday, January 1, 2022369090000177977000
Sunday, January 1, 2023402466000173612000
Loading chart...

In pursuit of knowledge

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, ACADIA Pharmaceuticals Inc. and Cytokinetics, Incorporated have taken distinct paths in optimizing these costs.

From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. This reflects their aggressive expansion strategy, which may have contributed to their market presence but also increased operational costs. In contrast, Cytokinetics maintained a more conservative approach, with expenses growing by approximately 900% over the same period. This strategy allowed them to focus resources on research and development, potentially leading to more sustainable growth.

As investors and industry watchers evaluate these companies, understanding their cost management strategies provides valuable insights into their long-term viability and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025